Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) SVP Sells $21,868.80 in Stock

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWDGet Free Report) SVP Andrew Davis sold 5,360 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $4.08, for a total transaction of $21,868.80. Following the completion of the transaction, the senior vice president now owns 284,685 shares of the company’s stock, valued at approximately $1,161,514.80. This trade represents a 1.85 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Ironwood Pharmaceuticals Stock Performance

NASDAQ IRWD traded down $0.29 on Wednesday, reaching $3.52. 1,613,600 shares of the company’s stock traded hands, compared to its average volume of 2,895,659. Ironwood Pharmaceuticals, Inc. has a fifty-two week low of $3.51 and a fifty-two week high of $15.70. The stock has a 50 day moving average price of $4.27 and a 200-day moving average price of $5.39. The firm has a market cap of $563.31 million, a price-to-earnings ratio of -127.00 and a beta of 0.47.

Ironwood Pharmaceuticals (NASDAQ:IRWDGet Free Report) last released its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.07). The company had revenue of $91.60 million for the quarter, compared to analysts’ expectations of $91.22 million. Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The firm’s quarterly revenue was down 19.4% on a year-over-year basis. During the same period in the prior year, the firm posted $0.12 EPS. As a group, equities research analysts anticipate that Ironwood Pharmaceuticals, Inc. will post 0.1 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. Leerink Partnrs upgraded shares of Ironwood Pharmaceuticals to a “hold” rating in a report on Monday, September 9th. StockNews.com lowered shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, November 12th. Capital One Financial downgraded shares of Ironwood Pharmaceuticals from an “overweight” rating to an “equal weight” rating and decreased their price objective for the company from $12.00 to $4.00 in a report on Thursday, August 8th. Wells Fargo & Company dropped their price objective on shares of Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating for the company in a report on Friday, August 9th. Finally, Craig Hallum decreased their price target on shares of Ironwood Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating for the company in a research note on Friday, August 9th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, Ironwood Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.40.

Get Our Latest Report on Ironwood Pharmaceuticals

Hedge Funds Weigh In On Ironwood Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its holdings in Ironwood Pharmaceuticals by 21.8% in the 1st quarter. Vanguard Group Inc. now owns 19,521,366 shares of the biotechnology company’s stock worth $170,031,000 after buying an additional 3,487,821 shares during the last quarter. Armistice Capital LLC grew its stake in shares of Ironwood Pharmaceuticals by 44.4% during the 2nd quarter. Armistice Capital LLC now owns 7,800,000 shares of the biotechnology company’s stock valued at $50,856,000 after buying an additional 2,400,000 shares during the period. Pacer Advisors Inc. lifted its holdings in shares of Ironwood Pharmaceuticals by 26.6% during the 3rd quarter. Pacer Advisors Inc. now owns 11,279,822 shares of the biotechnology company’s stock valued at $46,473,000 after acquiring an additional 2,372,183 shares in the last quarter. Kynam Capital Management LP acquired a new stake in shares of Ironwood Pharmaceuticals in the 1st quarter valued at about $14,154,000. Finally, Renaissance Technologies LLC grew its position in shares of Ironwood Pharmaceuticals by 20.7% during the 2nd quarter. Renaissance Technologies LLC now owns 8,571,898 shares of the biotechnology company’s stock valued at $55,889,000 after buying an additional 1,472,097 shares during the last quarter.

Ironwood Pharmaceuticals Company Profile

(Get Free Report)

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.

Read More

Insider Buying and Selling by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.